![](https://news.europawire.eu/wp-content/uploads/2020/05/Rare-disease-Enhertu-of-AstraZeneca-and-Daiichi-Sankyo-now-with-Orphan-Drug-Designation-in-the-US-for-treatment-of-gastric-cancer-144x144.jpg)
(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release